ClinicalTrials.gg
CompletedNCT06392360Updated Mar 11, 2025

Betaine, Exercise Performance, and Gut Permeability

An interventional study of Betaine and Placebo in Metabolic Disturbance and Permeability; Increased, sponsored by Appalachian State University. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Appalachian State University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will determine if ingestion of 3 g/d betaine versus placebo for two weeks prior to a 60-km cycling time trial will improve performance, moderate exercise-induced gut permeability, and improve metabolic recovery.

Read the detailed description

This study will employ a randomized crossover design. Study participants will be randomized to two trials using double-blinded, placebo-controlled procedures. The supplement capsules (betaine and placebo) will be coded by the sponsor, with the double-blind code held until after all study samples have been analyzed. Subjects will come to the lab for orientation/baseline testing, pre-and post-supplementation blood sample collections (2 weeks supplementation with betaine or placebo), two 60-km cycling sessions, and two 24-h recovery lab sessions (thus 8 total lab visits). Subjects will complete a COVID-19 screening questionnaire before entering the lab (all visits). The total amount of time subjects will be asked to volunteer for this study is about 18 hours at the Human Performance Laboratory (over a 6-week period).

A. Orientation (Visit #1). Subjects will report to the lab in an overnight fasted state. Subjects will voluntarily sign IRB-approved consent forms and complete questionnaires (delayed onset of muscle soreness or DOMS, Profile of Mood States or POMS). Demographic, health, and training histories will be acquired with questionnaires. A blood sample will be collected. Body composition and total body water will be measured using 8-point bioelectrical impedance (BIA). Subjects will ingest a standardized sugar solution containing lactulose 5 g, 13C mannitol 100 mg, mannitol 1.9 g, and rhamnose 1 g in a total of 450 ml water (SS, calculated osmolality 69 mosmol/kg). An increase in the post-exercise lactulose/13C mannitol ratio (L/M) will be used as an indicator of increased gut permeability. All urine excreted for five hours post SS ingestion will be collected in a urine collection container. Subjects will be urged to drink water after the first hour of the test to ensure adequate urine output. The Boost beverage will be consumed at 7 kcal/kg 1.5 h post SS ingestion (to simulate what occurs post-exercise). The urine collection container will be placed in the refrigerator until they are returned to the lab the next day. The total urine volume will be measured with four 10 ml aliquots frozen in a minus 80°C freezer until analysis.

B. Baseline Testing/Pre-Supplementation (Visit #2). Subject will return the urine collection container to the lab the day after Visit #1. Body composition will be measured with the Bod Pod body composition analyzer (Life Measurement, Concord, CA). Study participants will be tested for maximal aerobic capacity (VO2max) during a graded, cycling test with continuous metabolic monitoring with the Cosmed CPET metabolic device (Cosmed, Rome, Italy). A 2-week supply of betaine or placebo capsules will be given to the participants. Subjects will consume 6 capsules per day, 3 with the first meal in the morning and 3 more with the last meal of the day.

DuraBeet Betaine supplement. DuraBeet® crystalline betaine is produced from beet molasses at the betaine crystallization plant, in Austria, according to strict European standards. The white crystalline betaine will be in 6 capsules (3 g/day). The placebo capsules will contain a white cellulose powder in identical looking capsules.

C. 60-km Cycling Session (Lab Visit #3): During the 3-day period prior to the 60-km cycling session, subjects will taper exercise training and ingest a moderate-carbohydrate diet using a food list restricting high fat foods, visible fats, and caffeine. Subjects will record all food and beverage intake in a 3-day food record with macro- and micro-nutrient intake calculated using the ESHA Food Processor nutrient analysis software program. Study participants will report to the Human Performance Lab in an overnight fasted state and provide a blood sample, ingest the supplement (3 capsules of betaine or placebo), and then cycle 60-km at the fastest pace possible while ingesting water alone (3 ml/kg every 15 minutes). Immediately following the cycling bout, subjects will ingest the gut permeability sugar solution (SS). Blood samples will be collected at 0 h, 1.5 h, 3.0 h, and 24-h post-exercise. All urine excreted for five hours after SS ingestion will be collected in a urine collection container.

Testing protocol during the lab sessions with the 60-km cycling session:

  1. 7:00 am: Provide blood sample, delayed onset of muscle soreness (DOMS) rating (1-10 scale), and profile of mood states ratings (POMS). Complete the symptom survey. Turn in the 3-day food record.
  2. 7:10 am: Ingest 3 capsules of betaine or placebo with 1 cup water.
  3. 7:30 am: Start the 60-km cycling session. Subjects will cycle on trainers at race pace for 60-km. Oxygen consumption, carbon dioxide production, respiratory exchange ratio, and ventilation will be measured using the Cosmed Quark CPET metabolic cart every 30 minutes. Subjects will consume 3 ml/kg water every 15 min. No other beverage or food containing energy or nutrients will be allowed during the 60-km exercise sessions.
  4. \~10:00 am to 1:00 pm: Subjects will ingest the 450 mL SS within the first minute of getting off the bicycle. Body composition and total body water will be measured using 8-point bioelectrical impedance (BIA). All urine excreted from 0-5 h after SS ingestion will be collected in a urine collection container. Blood samples will be taken via venipuncture immediately after completing the cycling session, and then 1.5-h, 3.0-h, and 24-h post-exercise. Subjects will be allowed to shower and change clothes. The DOMS and POMS questionnaires will be administered each time blood samples are collected. Body composition and total body water will be measured using 8-point BIA each time blood samples are collected. Subjects will ingest no food or beverage other than water (7 ml/kg during the 1.5 h post-exercise period; this will take into account the 450 ml sugar solution; no water will be ingested during the first hour post-SS intake). After the 1.5 h post-exercise blood draw, subjects will ingest a Boost beverage (7 kcal/kg body weight). Another blood sample will be collected 3-h post-exercise. Afterwards, subjects will leave the lab with instructions to complete the 5h urine collection, put the container in the refrigerator, and then bring the urine container to the lab the next morning. Subjects will ingest 3 supplement capsules with the last meal of the day.

LAB VISIT #4: Subjects will return the next morning after the cycling session to provide another blood sample, turn in the 5-h urine container, and complete DOMS and POMS questionnaires. Body composition and total body water will be measured using 8-point BIA.

D. Washout/Crossover/Repeat

Subjects will engage in a 2-week washout period without the supplements, crossover to the opposite supplement arm, and then repeat all procedures except for the consent process, completion of the medical health questionnaire, body composition testing, and VO2 max testing (Lab visits #5,6,7,8). Subjects will maintain the study diet and normal exercise training routines during the 2-week washout period.

02

Conditions studied

  • Metabolic Disturbance
  • Permeability; Increased

Browse trials for

Keywords

  • betaine
  • exercise
  • gut permeability
  • metabolomics
03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's enrollment of 23 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

Appalachian State University is the lead sponsor of 41 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cyclists, ages 18-65 years, and capable of cycling 60-km in the laboratory at 70% VO2max (close to race pace).
  • Non-smoker, and generally healthy and without gastrointestinal diseases (irritable bowel syndrome, chronic nausea, vomiting, and diarrhea, Crohn's disease, Celiac disease, diverticulosis) or chronic diseases including cardiovascular disease (e.g., heart disease, stroke), cancer, type 1 and 2 diabetes, rheumatoid arthritis. Categorized as "low risk" using the American College of Sports Medicine screening questionnaire.
  • Agree to train normally, maintain weight, and avoid the regular use of large-dose vitamin and mineral supplements, herbs, and medications that influence inflammation (especially NSAIDs) for the duration of the 6-week study and at least a 2-week period prior to the study.
  • Agree to taper their exercise routine prior to each of the 2 lab cycling sessions.
  • Agree to restrict beet, wheat bran, wheat germ, and spinach diet intake and avoid other betaine supplements (other than what is provided in the supplement) during the entire 6-week study.

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with study requirements.
  • Females trying to become pregnant, or currently pregnant or breastfeeding.
  • Nonpregnant adults who weigh less than 110 pounds.
  • Any other concurrent condition which, in the opinion of the principal investigator (PI), would preclude participation in this study or interfere with compliance.
  • Current diagnosis of gastrointestinal disease, cardiovascular disease, diabetes, or cancer (except for non-melanoma skin cancer).
  • History of sensitivity to betaine and beets.
  • History of adverse symptoms to lactulose, mannitol, and rhamnose sugars.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Betaine

    3 grams per day in 6 capsules, white crystalline betaine powder produced from beet molasses

    Dietary Supplement: Betaine

  • Placebo comparator
    Placebo

    3 grams per day in 6 capsules, white cellulose powder

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBetaine

    White betaine powder

  • Dietary supplementPlacebo

    White placebo powder

06

What researchers measure

Primary outcomes

  1. Exercise Performance

    60-km cycling time trial

    Time frame: After 2-weeks supplementation with betaine compared to after 2-weeks supplementation with placebo

Secondary outcomes

  1. Gut permeability

    Urine concentrations of post-exercise lactulose/13C mannitol ratio (L/M)

    Time frame: Change from pre-supplementation levels to 5 hours post-exercise

  2. Changes in plasma gut permeability sugars including mannitol, lactulose, rhamnose, and sucrose from targeted metabolomics using LC-MS/MS analysis (relative intensities)

    Targeted metabolomics to assess plasma metabolites (sugars) from LC-MS/MS analysis (relative intensities) \[Time Frame: Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours

    Time frame: Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours-, and 24 hours-post-exercise

07

Study locations

2 sites
  • Appalachian State University Human Performance Lab, North Carolina Research Campus
    Kannapolis, North Carolina 28081, United States
  • AppState-North Carolina Research Campus Human Performance Lab
    Kannapolis, North Carolina 28081, United States
08

References and documents

Individual participant data

Plan to share: Yes — Will share data upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: March 1, 2025, indefinitely

Access criteria: Upon reasonable request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06392360
Lead sponsor
Appalachian State University
Collaborators
AGRANA
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
Aug 13, 2024
Primary completion
Feb 11, 2025
Completion
Feb 11, 2025
Last update
Mar 11, 2025

Study contacts

David C Nieman, DrPH
principal investigator · Appalachian State Univ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Betaine

Start the discussion